Quick Takeaways
- This page summarizes Solomon Moshkevich's Form 4 filing for Natera, Inc. (NTRA).
- 6 reported transactions and 1 derivative row are listed below.
- Filing timestamp: 03 Mar 2026, 21:05.
Solomon Moshkevich - 27 Feb 2026 Form 4 Insider Report for Natera, Inc. (NTRA)
- Signature
- /s/ Tami Chen, Attorney-in-Fact
- Issuer symbol
- NTRA
- Transactions as of
- 27 Feb 2026
- Net transactions value
- -$550,396
- Form type
- 4
- Filing time
- 03 Mar 2026, 21:05:04 UTC
- Previous filing
- 04 Feb 2026
- Next filing
- 11 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Solomon Moshkevich filed Form 4 for Natera, Inc. (NTRA) on 03 Mar 2026."
What Changed
- Previous filing in this sequence was filed on 04 Feb 2026.
- Current net transaction value: -$550,396.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Reporting Owners (1)
| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Moshkevich Solomon | PRESIDENT, CLINICALDIAGNOSTICS | C/O NATERA, INC., 13011 MCCALLEN PASS BUILDING A SUITE 100, AUSTIN | /s/ Tami Chen, Attorney-in-Fact | 03 Mar 2026 | 0002010019 |
Transactions Table
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NTRA | Common Stock | Award | +10,051 | +7.3% | 147,898 | 27 Feb 2026 | Direct | F1, F2 | ||
| transaction | NTRA | Common Stock | Options Exercise | $49,149 | +5,125 | +3.5% | $9.59 | 153,023 | 02 Mar 2026 | Direct | |
| transaction | NTRA | Common Stock | Sale | $185,114 | -931 | -0.61% | $198.83 | 152,092 | 02 Mar 2026 | Direct | F3, F4 |
| transaction | NTRA | Common Stock | Sale | $318,971 | -1,594 | -1% | $200.11 | 150,498 | 02 Mar 2026 | Direct | F3, F5 |
| transaction | NTRA | Common Stock | Sale | $95,460 | -475 | -0.32% | $200.97 | 150,023 | 02 Mar 2026 | Direct | F3, F6 |
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NTRA | Stock Option (right to buy) | Options Exercise | $0 | -5,125 | -100% | $0.000000 | 0 | 02 Mar 2026 | Common Stock | 5,125 | $9.59 | Direct | F7 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | Represents the issuance of Restricted Stock Units ("RSUs") to the Reporting Person. The RSUs vest over four years. 25% of the RSUs vest on March 1, 2027 and the remaining RSUs vest in 12 equal quarterly installments thereafter. |
| F2 | Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. |
| F3 | The sale of shares was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 26, 2024. |
| F4 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.42 to $199.25 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F5 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.6750 to $200.5100 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F6 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.72 to $201.16 per share, inclusive. The holder undertakes to provide, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F7 | The option shares are fully exercisable. |